Avaí Bio, Inc. (AVAI)
OTCMKTS
· Delayed Price · Currency is USD
0.348
+0.018 (5.45%)
At close: Apr 28, 2026
Avaí Bio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
48.11M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Investview | 36.26M |
| Grow Capital | 22.15M |
| Latch | 70.12M |
| CreateAI Holdings | 96.00K |
| Ankam | 325.00K |
| Nextech3D.AI | 1.33M |
| CreditRiskMonitor.com | 20.12M |
Avaí Bio News
- 21 days ago - Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference - PRNewsWire
- 2 months ago - Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards - PRNewsWire
- 2 months ago - Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website - PRNewsWire
- 3 months ago - Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium - PRNewsWire
- 4 months ago - Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment - PRNewsWire
- 5 months ago - Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival - PRNewsWire
- 5 months ago - THE CRITICAL LIST: 5 Stocks Anchoring the New Economy - GlobeNewsWire
- 5 months ago - Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies - Business Wire